What is the Genpharmasec Ltd share price today?

The share price of BSE:GENPHARMA-X on 01 Oct 2026 (as of 15:05:53 IST) is ₹1.07.

What is the BSE:GENPHARMA-X 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the BSE:GENPHARMA-X 52 week high low range shows a high of ₹1.92 and a low of ₹0.75.

What is the Genpharmasec Ltd market cap?

As on 01 Oct 2026, Genpharmasec Ltd market cap is ₹620166000.

What is the shareholding pattern of Genpharmasec Ltd Stock?

The shareholding pattern of Genpharmasec Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 29.98% Foreign Institutional Investors (FII): 0% Domestic Institutional Investors (DII): 0% Mutual Funds: 0% Retail & Others: 70.02% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Genpharmasec Ltd?

The Price-to-Earnings (PE) ratio of Genpharmasec Ltd is 0, and the Price-to-Book (PB) ratio is 1.606, as on 01 Oct 2026.

Genpharmasec Share Price

1.04+0.00 (+1.96%)

-35.00% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+1.96%

1 Week

+5.05%

1 Month

-5.45%

3 Month

-0.95%

6 Month

-18.11%

YTD

-20.61%

1 Year

-35.00%

5 Year

-75.19%

10 Year

Max

-88.22%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

1.02

0.98

0.91

0.90

0.75

High

1.09

1.14

1.36

1.79

About

Adi Rasayan Ltd is engaged in manufacturing and trading in organic and inorganic chemicals dyes and pigments.

Trading

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

ADANIENT-ANSE

CPPLUS-ANSE

PREMIERENE-ANSE

AEGISLOG-ANSE

REDINGTON-ANSE

HONASA-ANSE

LLOYDSENT-ANSE

CELLO-ANSE

JSLL-ANSE

SREEL-TNSE

GENPHARMA-XNSE

LTP

1W Low

1W High

Market cap (₹)

2590+12 (0.47%)

2559

2634

3,53,335Cr

3890+78.55 (2.06%)

3624.65

3947.90

47,150Cr

888.9+22.9 (2.64%)

850

894

40,334Cr

1180.25+82.8 (7.54%)

1082

1253.90

38,645Cr

335.35+8.6 (2.63%)

315

356.75

25,810Cr

456+13.95 (3.16%)

435.40

465.55

14,727Cr

60.57-0.44 (-0.72%)

59.72

62.86

9,182Cr

341.7+13.1 (3.99%)

326.05

353.95

7,800Cr

343+9.3 (2.79%)

330.20

350.05

4,225Cr

264.2+14.2 (5.68%)

248.40

271.50

607Cr

1.04+0.05 (5.05%)

0.97

1.09

56Cr

Genpharmasec Share Price

1.04+0.00 (+1.96%)

-35.00% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years-

3 years-

Last year11%

Compounded Profit Growth

10 years-

5 years-

3 years-

Last year827%

Stock Price CAGR

10 years-

5 years-24%

3 years-23%

1 year-35%

Return on Equity

10 years3%

5 years3%

3 years3%

Last year2%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	-	-	11%
-	-	-	827%
-	-24%	-23%	-35%
3%	3%	3%	2%

Peer Comparison

Symbol

ADANIENT-A

CPPLUS-A

PREMIERENE-A

AEGISLOG-A

REDINGTON-A

HONASA-A

LLOYDSENT-A

CELLO-A

JSLL-A

SREEL-T

GENPHARMA-X

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
2,590	₹353335 Cr	61.58	11.02	97.19	₹9339 Cr
3,890	₹47150 Cr	98.79	12.07	43.68	₹368 Cr
888.9	₹40334 Cr	24.22	10.2	45.28	₹1510 Cr
1,180.25	₹38645 Cr	29.01	7.42	44.04	₹898 Cr
335.35	₹25810 Cr	15.17	6.22	24.36	₹1490 Cr
456	₹14727 Cr	59.17	2.77	8.99	₹200 Cr
60.57	₹9182 Cr	81.77	0.38	0.91	₹283 Cr
341.7	₹7800 Cr	24.93	3.32	17.46	₹332 Cr
343	₹4225 Cr	17.87	5.31	23.32	₹222 Cr
264.2	₹607 Cr	18.5	3.02	14.74	₹29 Cr
1.04	₹56 Cr	—	0	0.04	₹56 L

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Mar 2023
₹86 Cr	₹50 Cr	₹55 Cr	₹40 Cr	₹33 Cr	₹12 Cr	₹14 Cr	₹8 Cr	₹6 Cr	₹5 Cr	₹10 Cr	₹6 Cr	₹8 Cr	₹6 Cr
₹1 Cr	₹37 L	₹1 Cr	₹98 L	₹47 L	₹70 L	₹94 L	₹81 L	₹75 L	₹57 L	₹31 L	₹14 L	₹15 L	₹6 L
₹87 Cr	₹50 Cr	₹56 Cr	₹41 Cr	₹33 Cr	₹13 Cr	₹15 Cr	₹9 Cr	₹7 Cr	₹6 Cr	₹11 Cr	₹7 Cr	₹8 Cr	₹6 Cr
₹85 Cr	₹49 Cr	₹54 Cr	₹42 Cr	₹34 Cr	₹11 Cr	₹15 Cr	₹8 Cr	₹6 Cr	₹5 Cr	₹10 Cr	₹6 Cr	₹8 Cr	₹6 Cr
₹3 Cr	₹1 Cr	₹3 Cr	-₹26 L	-₹80,000	₹2 Cr	-₹8 L	₹2 Cr	₹87 L	₹75 L	₹30 L	₹16 L	₹11 L	₹27 L
₹44 L	₹40 L	₹48 L	₹41 L	₹23 L	₹12 L	₹11 L	₹16 L	₹7 L	₹10 L	₹16 L	₹50,000	₹7 L	₹6 L
₹2 Cr	₹26 L	₹2 Cr	-₹1 Cr	-₹80 L	₹1 Cr	-₹44 L	₹1 Cr	₹50 L	₹49 L	₹11 L	₹3 L	₹4 L	₹20 L
₹1 Cr	-₹17 L	₹1 Cr	-₹83 L	-₹1 Cr	₹1 Cr	-₹28 L	₹76 L	₹70 L	₹29 L	₹49 L	₹6 L	₹60,000	₹1 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2025	Mar 2024	Mar 2023
—	—	—
₹55 Cr	₹55 Cr	₹28 Cr
₹10 Cr	₹9 Cr	-₹12 Cr
₹10 Cr	₹9 Cr	-₹12 Cr
₹65 Cr	₹64 Cr	₹15 Cr
₹12 L	₹14 L	₹0
₹3 Cr	₹3 Cr	₹2 Cr
-₹46 L	-₹43 L	-₹85 L
₹2 Cr	₹68 L	₹0
₹1 L	₹0	₹0
₹4 Cr	₹3 Cr	₹2 Cr
—	—	—
₹8 Cr	₹2 Cr	₹1 Cr
₹1 Cr	₹32 L	₹9 L
₹0	₹0	₹60 L
₹56 L	₹0	₹0
₹10 Cr	₹3 Cr	₹2 Cr
₹79 Cr	₹71 Cr	₹19 Cr
₹2 L	₹2 L	₹2 L
₹3 Cr	₹3 Cr	₹3 Cr
—	—	—
₹8 Cr	₹93 L	₹15 L
₹89 L	₹10 L	₹5 L
₹8 Cr	₹84 L	₹10 L
₹19 Cr	₹18 Cr	₹0
₹19 Cr	₹18 Cr	₹0
₹24 Cr	₹11 Cr	₹0
₹2 Cr	₹0	₹0
₹52 Cr	₹30 Cr	₹10 L
—	—	—
₹0	₹2 Cr	₹95 L
₹8 Cr	₹9 Cr	₹10 Cr
₹14 Cr	₹9 Cr	₹6 Cr
₹5 Cr	₹19 Cr	₹2 Cr
₹4 L	₹38 L	₹2 L
₹21 L	₹2 Cr	₹58 L
₹27 Cr	₹41 Cr	₹19 Cr
₹17 Cr	₹38 Cr	₹17 Cr
₹79 Cr	₹71 Cr	₹19 Cr
₹1	₹1	₹1
₹1	₹1	₹0

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Closing Cash & Cash Equivalent

Mar 2025	Mar 2024	Mar 2023
₹2 Cr	₹25 L	₹28 L
-₹1 Cr	₹39 L	₹16 L
₹2 Cr	-₹4 Cr	-₹4 Cr
₹3 Cr	-₹3 Cr	-₹3 Cr
₹3 Cr	-₹3 Cr	-₹3 Cr
-₹15 Cr	-₹28 Cr	₹36 L
-₹1 Cr	₹48 Cr	₹3 Cr
-₹14 Cr	₹17 Cr	₹39 L
₹19 Cr	₹2 Cr	₹2 Cr
₹5 Cr	₹19 Cr	₹2 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Genpharmasec Share Price

1.04+0.00 (+1.96%)

-35.00% past 1 Year

02 Jan 25+9D

Bid/Ask

Price

Greeks

Stradle

Custom

CALLS

Qty/ots

PUTS

Open a free Demat account in minutes to start investing and screening .

Genpharmasec Share Price

1.04+0.00 (+1.96%)

-35.00% past 1 Year

Shareholding summary

Promoters

32.06%

FII

DII

Others

67.94%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
32.06%	29.98%	29.98%	29.98%	29.98%	29.98%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
67.94%	70.02%	70.02%	70.02%	70.02%	70.02%

Bulk & block deals

Name

Rajesh Mirchumal Sadhwani

Divya Deven Pathak

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
31 Aug 2026	Purchase	42 L	₹1.05	40 L	Bulk	0.722387	BSE
28 Aug 2026	Purchase	50.50 L	₹1.01	50 L	Bulk	0.902984	BSE
30 Dec 2024	Sell	1.03 Cr	₹2.95	35 L	Bulk	0.632089	BSE

Insider trading & SAST

Client name

Rajesh Sadhwani

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
01 Sep 2026	Promoter and Director	Acquisition	1.173879	15.26	71.50 L	₹1.10	65 L	31 Aug 2026 - 01 Sep 2026	Market Purchase	8,45,00,000	Insider Trading	—	Equity
31 Aug 2026	Promoter and Director	Acquisition	0.902984	14.09	50.50 L	₹1.01	50 L	28 Aug 2026	Market Purchase	7,80,00,000	Insider Trading	—	Equity

Genpharmasec Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Genpharmasec Share Price

Genpharmasec Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Genpharmasec Share Price

Genpharmasec Share Price

Oscillators

Moving averages

Genpharmasec Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Genpharmasec Share Price

Corporate Actions

Company details

Genpharmasec Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Genpharmasec Share Price

News

Genpharmasec - Quaterly Results

Genpharmasec reports Profit after tax of 2.32 Crores, in the March 2026 quarter

Genpharmasec informs about directors meeting

Genpharmasec - Quaterly Results

Genpharmasec reports Profit after tax of 75.50 Lakhs, in the December 2025 quarter

Genpharmasec informs about confirmation certificate

Genpharmasec informs about trading window closure

Genpharmasec reports Profit after tax of 81.50 Lakhs, in the September 2025 quarter

Genpharmasec informs about trading window closure

Genpharmasec informs about press release

Genpharmasec informs about board meeting

Genpharmasec informs about press release

Genpharmasec - Quaterly Results

Genpharmasec reports Profit after tax of 1.56 Crores, in the June 2025 quarter

Genpharmasec - Quaterly Results

Genpharmasec - Quaterly Results

Genpharmasec acquires 70% stake in Derren Healthcare

Genpharmasec reports Profit after tax of Rs -22.70 Lakhs, in the March 2025 quarter

Genpharmasec - Quaterly Results

Genpharmasec - Quaterly Results

Genpharmasec Ltd Share Price Today

Genpharmasec Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator